New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation, disorders and cancers

Skin Pharmacology and Physiology

Volumn 17, Issue 4, 2004, Pages 153-166

  Mimeault, M ^a   Bonenfant, D ^b   Batra, S K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

Cancers; Ceramides; Epidermal growth factor receptor; Epithelial cell differentiation; Permeability barrier; Skin disorders

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; AG 1571; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CARBON DIOXIDE; CARMUSTINE; CERAMIDE DERIVATIVE; CISPLATIN; CYTARABINE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLAVANOID; FLUOROURACIL; GEFITINIB; INTERLEUKIN 2; ISOFLAVONE DERIVATIVE; OGT 2378; OLIGONUCLEOTIDE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SILYMARIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARBON DIOXIDE LASER; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CRYOTHERAPY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EPIDERMIS; EPIDERMIS HYPERPLASIA; GENE OVEREXPRESSION; HUMAN; KERATINOCYTE; MELANOMA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN DISEASE;

ADMINISTRATION, CUTANEOUS; CELL DIFFERENTIATION; CERAMIDES; DRUG THERAPY, COMBINATION; EPIDERMIS; PERMEABILITY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN; SKIN DISEASES; SKIN NEOPLASMS; UP-REGULATION;

EID: 3242799070     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078818     Document Type: Review

References (183)

1. Elias PM: Epidermal lipids, barrier function, and desquamation. J Invest Dermatol 1983;80: 44S-49S.
2. Lampe MA, Burlingame AL, Whitney J, Williams ML, Brown BE, Roitman E, Elias PM: Human stratum corneum lipids: Characterization and regional variations. J Lipid Res 1983; 24:120-130.
3. Elias PM, Menon GK: Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res 1991;24:1-26.
4. Feingold KR, Man MQ, Menon GK, Cho SS, Brown BE, Elias PM: Cholesterol synthesis is required for cutaneous barrier function in mice. J Clin Invest 1990;86:1738-1745.
5. Holleran WM, Man MQ, Gao WN, Menon GK, Elias PM, Feingold KR: Sphingolipids are required for mammalian epidermal barrier function. Inhibition of sphingolipid synthesis delays barrier recovery after acute perturbation. J Clin Invest 1991;88:1338-1345.
6. Madison KC: Barrier function of the skin: 'La raison d'être' of the epidermis. J Invest Dermatol 2003;121:231-241.
7. Martini MC: Biochemical analysis of epidermal lipids. Pathol Biol 2003;51:267-270.
8. Claudy A: Cutaneous lipids: From physiology to the clinical. Pathol Biol 2003;51:260-263.
9. Bouwstra JA, Gooris GS, Dubbelaar FER, Weerheim AMI, Ponec M: pH, cholesterol sulfate, and fatty acids affect the stratum corneum lipid organization. J Invest Dermatol Symp Proc 1998;3:69-74.
10. Bouwstra JA, Gooris GS, Dubbelaar FER, Weerheim AMI, Ijzerman AP, Ponec M: Role of ceramide 1 in the molecular organization of the stratum corneum lipids. J Lipid Res 1998; 39:186-196.
11. Di Nardo A, Wertz P, Gianneti A, Seidenari S: Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol 1998;78:27-30.
12. Harding CR: The stratum corneum: Structure and function in health and disease. Dermatol Ther 2004;17:6-15.
13. Harding CR, Moore AE, Rogers JS, Meldrum H, Scott AE, McGlone FP: Dandruff: A condition characterized by decreased levels of intercellular lipids in scalp stratum corneum and impaired barrier function. Arch Dermatol Res 2002;294:221-230.
14. Macheleidt O, Kaiser HW, Sandhoff K: Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis. J Invest Dermatol 2002;119:166-173.
15. Ishibashi M, Arikawa J, Okamoto R, Kawashima M, Takagi Y, Ohguchi K, Imokawa G: Abnormal expression of the novel epidermal enzyme, glucosylceramide deacylase, and the accumulation of its enzymatic reaction product, glucosylsphingosine, in the skin of patients with atopic dermatitis. Lab Invest 2003;83: 397-408.
16. Okamoto R, Arikawa J, Ishibashi M, Kawashima M, Takagi Y, Imokawa G: Sphingosylphosphorylcholine is upregulated in the stratum corneum of patients with atopic dermatitis. J Lipid Res 2003;44:93-102.
17. Zheng Y, Peng Z, Wang Y, Tan S, Xi Y, Wang G: Alteration and significance of heparin-binding epidermal-growth-factor-like growth factor in psoriatic epidermis. Dermatology 2003;207: 22-27.
18. Ponec M, Gibbs S, Weerheim A, Kempenaar J, Mulder A, Mommaas AM: Epidermal growth factor and temperature regulate keratinocyte differentiation. Arch Dermatol Res 1997;289: 317-326.
19. Jung EM, Griner RD, Mann-Blakeney R, Bollag WB: A potential role for ceramide in the regulation of mouse epidermal keratinocyte proliferation and differentiation. J Invest Dermatol 1998;110:318-323.
20. Hansen LA, Woodson RL, Holbus S, Strain K, Lo YC, Yuspa SH: The epidermal growth factor receptor is required to maintain the proliferative population in the basal compartment of epidermal tumors. Cancer Res 2000;60:3328-3332.
21. Pasonen-Seppanen S, Karvinen S, Torronen K, Hyttinen JM, Jokela T, Lammi MJ, Tammi MI, Tammi R: EGF upregulates, whereas TGF-beta downregulates, the hyaluronan synthases Has2 and Has3 in organotypic keratinocyte cultures: Correlations with epidermal proliferation and differentiation. J Invest Dermatol 2003;120:1038-1044.
22. Gniadecki R, Bang B: Flotillas of lipid rafts in transit amplifying cell-like keratinocytes. J Invest Dermatol 2003;121:522-528.
23. Sparrow LE, Heenan PJ: Differential expression of epidermal growth factor receptor in melanocytic tumors demonstrated by immunohistochemistry and mRNA in situ hybridization. Australas J Dermatol 1999;40:19-24.
24. Krahn G, Leiter U, Kaskel P, Udart M, Utikal J, Bezold G, Peter RU: Coexpression patterns of EGFR, HER2, HER3 and HER4 in nonmelanoma skin cancer. Eur J Cancer 2001;37: 251-259.
25. Stoll SW, Kansra S, Peshick S, Fry DW, Leopold WR, Wiesen JF, Sibilia M, Zhang T, Werb Z, Derynck R, Wagner EF, Elder JT: Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes. Neoplasia 2001;3:339-350.
26. Gordon-Thomson C, Mason RS, Moore GP: Regulation of epidermal growth factor receptor expression in human melanocytes. Exp Dermatol 2001;10:321-328.
27. Udart M, Utikal J, Krahn GM, Peter RU: Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia 2001;3:245-254.
28. Wan Y, Belt A, Wang Z, Voorhees J, Fisher G: Transmodulation of epidermal growth factor receptor mediates IL-1 beta-induced MMP-1 expression in cultured human keratinocytes. Int J Mol Med 2001;7:329-334.
29. Polsky D, Cordon-Cardo C: Oncogenes in melanoma. Oncogene 2003;22:3087-3091.
30. Guzman E, Langowski JL, Owen-Schaub L: Mad dogs Englishmen and apoptosis: The role of cell death in UV-induced skin cancer. Apoptosis 2003;8:315-325.
31. Ichihashi M, Ueda M, Budiyanto A, Bito T, Oka M, Fukunaya M, Tsuru K, Horikawa T: UV-induced skin damage. Toxicology 2003; 189:21-39.
32. Yerebakan O, Ciftcioglu MA, Akkaya BK, Yilmaz E: Prognostic value of Ki-67, CD31 and epidermal growth factor receptor expression in basal cell carcinoma. J Dermatol 2003;30:33-41.
33. Vogt PM, Lehnhardt M, Wagner D, Jansen V, Krieg M, Steinau HU: Determination of endogenous growth factors in human wound fluid: Temporal presence and profiles of secretion. Plast Reconstr Surg 1998;102:117-123.
34. Gibbs S, Silva Pinto AN, Murli S, Huber M, Hohl D, Ponec M: Epidermal growth factor and keratinocyte growth factor differentially regulate epidermal migration, growth and differentiation. Wound Repair Regen 2000;8: 192-203.
35. Carpenter G: The EGF receptor: A nexus for trafficking and signaling. Bioassays 2000;22: 697-707.
36. Mimeault M: New advances on the structural and biological functions of the ceramide in apoptotic/necrotic cell death and cancer. FEBS Lett 2002;530:9-16.
37. Gniadecki R, Christoffersen N, Wulf HC: Cholesterol-rich plasma membrane domains (lipid rafts) in keratinocytes: Importance in the baseline and UVA-induced generation of reactive oxygen species. J Invest Dermatol 2002;118: 582-588.
38. Kim YN, Dam P, Bertics PJ: Caveolin-1 phosphorylation in human squamous and epidermoid carcinoma cells: Dependence on ErbB1 expression and Src activation. Exp Cell Res 2002;280:134-147.
39. Hudson LG, McCawley LJ: Contributions of the epidermal growth factor receptor to keratinocyte motility. Microsc Res Tech 1998;43: 444-455.
40. Sayama K, Hanakawa Y, Shirakata Y, Yamasaki K, Sawada Y, Sun L, Yamanishi K, Ichijo H, Hashimoto K: Apoptosis signal-regulating kinase 1 (ASK1) is an intracellular inducer of keratinocyte differentiation. J Biol Chem 2001; 276:999-1004.
41. Allombert-Blaise C, Tamiji S, Mortier L, Fauvel H, Tual M, Delaporte E, Piette F, DeLassale EM, Formstecher P, Marchetti P, Polakowska R: Terminal differentiation of human epidermal keratinocytes involves mitochondria-and caspase-dependent cell death pathway. Cell Death Differ 2003;10:850-852.
42. Lippens S, Kockx M, Knaapen M, Mortier L, Polakowska R, Verheyen A, Garmyn M, Zwijsen A, Formstecher P, Huylebroeck D, Vandenabeele P, Declercq W: Epidermal differentiation does not involve the proapoptotic executioner caspases but is associated with caspase 14 induction and processing. Cell Death Differ 2000;7:1218-1224.
43. Vielhaber G, Pfeiffer S, Brade L, Lindner B, Goldmann T, Vollmer E, Hintze U, Wittern KP, Wepf R: Localization of ceramide and glucosylceramide in human epidermis by immunogold electron microscopy. J Invest Dermatol 2001;117:1126-1136.
44. Doering T, Brade H, Sandhoff K: Sphingolipid metabolism during epidermal barrier development in mice. J Lipid Res 2002;43:1727-1733.
45. Madison KC, Sando GN, Howard EJ, True CA, Gilbert D, Swartzendruber DC, Wertz PW: Lamellar granule biogenesis: A role for ceramide glucosyltransferase, lysosomal enzyme transport and the Golgi. J Investig Dermatol Symp Proc 1998;3:80-86.
46. Bektas M, Orfanos CE, Geilen CC: Different vitamin D analogues induce sphingomyelin hydrolysis and apoptosis in the human keratinocyte cell line HaCaT. Cell Mol Biol 2000;46: 111-119.
47. Uchida Y, Hara M, Nishio H, Sidransky E, Inoue S, Otsuka F, Suzuki A, Elias PM, Holleran WM, Hamanaka S: Epidermal sphingomyelins are precursors for selected stratum corneum ceramides. J Lipid Res 2000;41:2071-2082.
48. Sugiki H, Hozumi Y, Maeshima H, Katagata Y, Mitsuhashi Y, Kondo S: C2-ceramide induces apoptosis in a human squamous cell carcinoma cell line. Br J Dermatol 2000;143: 1154-1163.
49. Hamanaka S, Hara M, Nishio H, Otsuka F, Suzuki A, Uchida Y: Human epidermal glucosylceramides are major precursors of stratum corneum ceramides. J Invest Dermatol 2002; 119:416-423.
50. Uchida Y, Hara M, Nishio H, Sidransky E, Inoue S, Otsuka F, Suzuki A, Elias PM, Holleran WM, Hamanaka S: Epidermal sphingomyelins are precursors for selected stratum corneum ceramides. J Lipid Res 2000;41:2071-2082.
51. Behne MJ, Barry NP, Hanson KM, Aronchik I, Clegg RW, Gratton E, Feingold K, Holleran WM, Elias PE, Mauro TM: Neonatal development of the stratum corneum pH gradient: Localization and mechanisms leading to emergence of optimal barrier function. J Invest Dermatol 2003;120:998-1006.
52. Matousek JL, Campbell KL: A comparative review of cutaneous pH. Vet Dermatol 2002; 13:293-300.
53. Behne MJ, Meyer JW, Hanson KM, Barry NP, Murata S, Crumrine D, Clegg RW, Gratton E, Holleran WM, Elias PM, Mauro TM: NHE1 regulates the stratum corneum permeability barrier homeostasis. J Biol Chem 2002;277: 47399-47406.
54. Coderch L, Lopez O, De la Maza A, Parra JL: Ceramides and skin function. Am J Clin Dermatol 2003;4:107-129.
55. Wertz PW: Lipids and barrier function of the skin. Acta Derm Venereol Suppl (Stockh) 2000;208:7-11.
56. Bouwstra JA, Honeywell-Nguyen PL, Gooris GS, Ponec M: Structure of the skin barrier and its modulation by vesicular formulations. Prog Lipid Res 2003;42:1-36.
57. Goldstein AM, Abramovitis W: Ceramides and the stratum corneum: Structure, function, and new methods to promote repair. Int J Dermatol 2003;42:256-259.
58. Pouliot R, Germain L, Auger FA, Tremblay N, Juhasz J: Physical characterization of the stratum corneum of an in vitro human skin equivalent produced by tissue engineering and its comparison with normal human skin by ATRFTIR spectroscopy and thermal analysis (DSC). Biochim Biophys Acta 1999;1439:341-352.
59. Ponec M, Boelsma E, Gibbs S, Mommaas M: Characterization of reconstructed skin models. Skin Pharmacol Appl Skin Physiol 2002;1:4-17.
60. Selvaratnam L, Cruchley AT, Navsaria H, Wertz PW, Hagi-Pavli EP, Leigh IM, Squier CA, Williams DM: Permeability barrier properties of oral keratinocyte cultures: A solely through omega-hydroxyl groups. Oral Dis 2001;7:252-258.
61. Mimeault M, Bonenfant D: FTIR spectroscopic analyses of the temperature and pH influences on the stratum corneum lipid phase behaviors and interactions. Talanta 2002;56: 395-405.
62. Pechtold LA, Abraham W, Potts RO: Characterization of the stratum corneum lipid matrix using fluorescence spectroscopy. J Investig Dermatol 1998;3:105-109.
63. Thewalt J, Kitson N, Araujo C, MacKay A, Bloom M: Models of stratum corneum intercellular membranes: The sphingolipid headgroup is a determinant of phase behavior in mixed lipid dispersions. Biochem Biophys Res Commun 1992;188:1247-1252.
64. Kitson N, Thewalt J, Lafleur M, Bloom M: A model membrane approach to the epidermal permeability barrier. Biochemistry 1994;33: 6707-6715.
65. Mendelsohn R, Moore DJ: Infrared determination of conformational order and phase behavior in ceramides and stratum corneum models. Methods Enzymol 2000;312:228-247.
66. Moore DJ, Rerek ME: Insights into the molecular organization of lipids in the skin barrier from infrared spectroscopy studies of stratum corneum lipid models. Acta Derm Venereol Suppl (Stockh) 2000;208:16-22.
67. Schreiner V, Gooris GS, Pfeiffer S, Lanzendorfer G, Wenck H, Diembeck W, Proksch E, Bouwstra JA: Barrier characateristics of different human skin types investigated with X-ray diffraction, lipid analysis, and electron microscopy imaging. J Invest Dermatol 2000;114: 654-660.
68. Mizushima H, Fukasawa J, Suzuki T: Phase behavior of artificial stratum corneum lipids containing a synthetic pseudo-ceramide: A study of the function of cholesterol. J Lipid Res 1996;37:361-367.
69. Abraham W, Downing DT: Lamellar structures formed by stratum corneum lipids in vitro: A deuterium nuclear magnetic resonance (NMR) study. Pharm Res 1992;9:1415-1421.
70. Bonte F, Pinguet P, Saunois A, Meybeck A, Beugin S, Ollivon M, Lesieur S: Thermotropic phase behavior of in vivo extracted human stratum corneum lipids. Lipids 1997;32:653-660.
71. McIntosh TJ, Stewart ME, Downing DT: X-ray diffraction analysis of isolated skin lipids: Reconstitution of intercellular lipid domains. Biochemistry 1996;35:3649-3653.
72. Glombitza B, Muller-Goymann CC: Influence of different ceramides on the structure of in vitro model lipid systems of the stratum corneum lipid matrix. Chem Phys Lipids 2002; 117:29-44.
73. Rehfeld SJ, Plachy WZ, Williams ML, Elias PM: Calorimetric and electron spin resonance examination of lipid phase transitions in human stratum corneum: Molecular basis for normal cohesion and abnormal desquamation in recessive X-linked ichthyosis. J Invest Dermatol 1988;91:499-505.
74. Elias PM, Ghadially R: The aged epidermal permeability barrier: Basis for functional abnormalities. Clin Geriatr Med 2002;18:103-120.
75. Geilen CC, Barz S, Bektas M: Sphingolipid signaling in epidermal homeostasis. Current knowledge and new therapeutic approaches in dermatology. Skin Pharmacol Appl Skin Physiol 2001;14:261-271.
76. Humbert P: Functional consequences of cutaneous lipid perturbation. Pathol Biol 2003;51: 271-274.
77. Higuchi K, Hara J, Okamoto R, Kawashima M, Imokawa G: The skin of atopic dermatitis patients contains a novel enzyme, glucosylceramide sphingomyelin deacylase, which cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. Biochem J 2000;350: 747-756.
78. Nanney LB, Ellis DL, Levine J, King LE: Epidermal growth factor receptors in idiopathic and virally induced skin diseases. Am J Pathol 1992;140:915-925.
79. Sergi C, Kahl P, Otto HF: Immunohistochemical localization of transforming growth factoralpha and epithelial growth factor receptor in human fetal developing skin, psoriasis and restrictive dermopathy. Pathol Oncol Res 2000; 6:250-255.
80. Haase I, Hunzelmann N: Activation of epidermal growth factor receptor/ERK signaling correlates with suppressed differentiation in malignant acanthosis nigricans. J Invest Dermatol 2002;118:891-893.
81. Mascia F, Mariani V, Girolomoni G, Pastore S: Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003;163:303-312.
82. Wang YN, Chang WC: Induction of the disease-associated keratin 16 gene expression by epidermal growth factor is regulated through cooperation of transcription factors Sp1 and c-Jun. J Biol Chem 2003;278:45848-45857.
83. Steude J, Kulke R, Christophers E: Interleukin-1-stimulated secretion of interleukin-8 and growth-related oncogene-alpha demonstrates greatly enhanced keratinocyte growth in human raft cultured epidermis. J Invest Dermatol 2002;119:1254-1260.
84. Pilgram GS, Vissers DC, van der Meulen H, Pavel S, Lavrijsen SP, Bouwstra JA, Koerten HK: Aberrant lipid organization in stratum corneum of patients with atopic dermatitis and lamellar ichthyosis. J Invest Dermatol 2001; 117:710-717.
85. Hara J, Higuchi K, Okamoto R, Kawashima M, Imokawa G: High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. J Invest Dermatol 2000;115:406-413.
86. Virag L, Szabo E, Bakondi E, Bai P, Gergely P, Hunyadi J, Szabo C: Nitric oxide-peroxynitrite-poly(ADP-ribose) polymerase pathway in the skin. Exp Dermatol 2002;11:189-202.
87. Gniadecki R, Gajkowska B, Bartosik J, Hansen M, Wulf HC: Variable expression of apoptotic phenotype in keratinocytes treated with ultraviolet radiation, ceramide, or suspended in semisolid methylcellulose. Acta Derm Venereol 1998;78:248-257.
88. Motta S, Monti M, Sesana S, Mellesi L, Ghidoni R, Caputo R: Abnormality of water barrier function in psoriasis. Role of ceramide fractions. Arch Dermatol 1994;130:452-456.
89. Arikawa J, Ishibashi M, Kawashima M, Takagi Y, Ichikawa Y, Imokawa G: Decreased levels of sphingosine, a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphylococcus aureus. J Invest Dermatol 2002;119:433-439.
90. Mao C, Xu R, Szulc ZM, Bielawski J, Becker KP, Bielawska A, Galadari SH, Hu W, Obeid LM: Cloning and characterization of a mouse endoplasmic reticulum alkaline ceramidase: An enzyme that preferentially regulates metabolism of very long chain ceramides. J Biol Chem 2003;278:31184-31191.
91. Ben-Bassat H, Levitzki A: Inhibitors of tyrosine kinases in the treatment of psoriasis. Isr Med Assoc J 2000;2:69-73.
92. Ben-Bassat H: Biological activity of tyrosine kinase inhibitors: Novel agents for psoriasis therapy. Curr Opin Investig Drugs 2001;2: 1539-1545.
93. Kucharekova M, Schalkwijk J, Van De Kerkhof PC, Van De Valk PG: Effect of a lipid-rich emollient containing ceramide 3 in experimentally induced skin barrier dysfunction. Contact Dermatitis 2002;46:331-338.
94. Okuda M, Yoshiike T, Ogawa H: Detergentinduced epidermal barrier dysfunction and its prevention. J Dermatol Sci 2002;30:173-179.
95. Cevc G, Blume G: Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta 1992;1104:226-232.
96. Tsai JC, Guy RH, Thornfeldt CR, Gao WN, Feingold KR, Elias PM: Metabolic approaches to enhance transdermal drug delivery. 1. Effect of lipid synthesis inhibitors. J Pharm Sci 1996;85:643-648.
97. Powell TJ, Ben-Bassat H, Klein BY, Chen H, Shenoy N, McCollough J, Narog B, Gazit A, Harzstark Z, Chaouat M, Levitzki R, Tang C, McMahon J, Shawver L, Levitzki A: Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors. Br J Dermatol 1999;141:802-810.
98. Sawa M, Tsukamoto T, Kiyoi T, Kurokawa K, Nakajima F, Nakada Y, Yokota K, Inoue Y, Kondo H, Yoshino K: New strategy for antidrug application: Development of metalloproteinase inhibitors as antipsoriatic drugs. J Med Chem 2002;45:930-936.
99. Berardesca E, Barbareschim M, Veraldi S, Pimpinelli N: Evaluation of efficacy of a skin lipid mixture in patients with irritant contact dermatitis allergic contact dermatitis or atopic dermatitis: A multicenter study. Contact Dermatitis 2001;45:280-285.
100. Asano-Kato N, Fukagawa K, Takano Y, Kawakita T, Tsubota K, Fujishima H, Takahashi S: Treatment of atopic blepharitis by controlling eyelid skin water retention ability with ceramide gel application. Br J Ophthalmol 2003;87:362-363.
101. Chamlin SL, Kao J, Frieden IJ, Sheu MY, Fowler AJ, Fluhr JW, Williams ML, Elias PM: Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: Changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002;47:198-208.
102. Loden M, Barany E: Skin-identical lipids versus petrolatum in the treatment of tapestripped and detergent-perturbed human skin. Acta Derm Venereol 2000;80:412-415.
103. Mao-Quiang M, Feingold KR, Thornfeldt CR, Elias PM: Optimization of physiological lipid mixtures for barrier repair. J Invest Dermatol 1996;106:1096-1101.
104. Yang L, Mao-Quiang M, Taljebini M, Elias PM, Feingold KR: Topical stratum corneum lipids accelerate barrier repair after tape stripping, solvent treatment and some but not all types of detergent treatment. Br J Dermatol 1995;133:679-685.
105. Zettersten EM, Ghadially R, Feingold KR, Crumrine D, Elias PM: Optimal ratios of topical stratum corneum lipids improve barrier recovery in chronologically aged skin. J Am Acad Dermatol 1997;37:403-408.
106. De Paepe K, Roseeuw D, Rogiers V: Repair of acetone- and sodium lauryl sulphate-damaged human skin barrier function using topically applied emulsions containing barrier lipids. J Eur Acad Dermatol Venereol 2002;16: 587-594.
107. Coderch L, De Pera M, Fonollosa J, De La Maza A, Parra J: Efficacy of stratum corneum lipid supplementation on human skin. Contact Dermatitis 2002;47:139-146.
108. Mao-Quiang M, Brown BE, Wu-Pong, Feingold KR, Elias PM: Exogenous nonphysiologic vs. physiologic lipids. Divergent mechanisms for correction of permeability barrier dysfunction. Arch Dermatol 1995;131:809-816.
109. Ogiso T, Niinaka N, Iwaki M: Mechanism for enhancement effect of lipid disperse system on percutaneous absorption. J Pharm Sci 1996;85:57-64.
110. Vavrova K, Hrabalek A, Dolezal P, Holas T, Zbytovska J: L-Serine and glycine based ceramide analogues as transdermal permeation enhancers: Polar head size and hydrogen bonding. Bioorg Med Chem Lett 2003;13: 2351-2353.
111. Hu Q, Shew CR, Bally MB, Madden TD: Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: Enhanced cellular uptake and biological effects. Biochim Biophys Acta 2001;1514:1-13.
112. Limmer BL: Nonmelanoma skin cancer: Today's epidemic. Tex Med 2001;97:56-58.
113. Kalady MF, White RR, Johnson JL, Tyler DS, Seigler HF: Thin melanoma: Predictive lethal characteristics from a 30-year clinical experience. Ann Surg 2003;238:528-535.
114. Katalinic A, Kunze U, Schafer T: Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: Incidence, clinical subtypes, tumor stages and localization (epidemiology of skin cancer). Br J Dermatol 2003;149:1200-1206.
115. Wan Y, Belt A, Wang Z, Voorhees J, Fisher G: Transmodulation of epidermal growth factor receptor mediates IL-1 beta-induced MMP-1 expression in cultured human keratinocytes. Int J Mol Med 2001;7:329-334.
116. Brenneisen P, Blaudschun R, Gille J, Schneider L, Hinrichs R, Wlaschek M, Eming S, Scharffetter-Kochanek K: Essential role of an activator protein-2 (AP-2)/specificity protein 1 (Sp1) cluster in the UVB-mediated induction of the human vascular endothelial growth factor in HaCaT keratinocytes. Biochem J 2003;369:341-349.
117. Yuspa SH, Hennings H, Dlugosz A, Tennenbaum T, Glick A: The role of growth factors in mouse skin tumor promotion and premalignant progression. Prog Clin Biol Res 1995; 391:39-48.
118. Bolontrade MF, Stern MC, Binder RL, Zenklusen JC, Gimenez-Conti IB, Contim CJ: Angiogenesis is an early event in the development of chemically induced skin tumors. Carcinogenesis 1998;19:2107-2113.
119. Satyamoorthy K, Herlyn M: Cellular and molecular biology of human melanoma. Cancer Biol Ther 2002;1:14-17.
120. Smith SH, Goldschmidt MH, McManus PM: A comparative review of melanocytic neoplasms. Vet Pathol 2002;39:651-678.
121. Gutman M, Even-Sapir E, Merimsky O, Trejo L, Klausner JM, Lev-Chelouche D: The role of interleukin-8 in the initiation and progression of human cutaneous melanoma. Anticancer Res 2002;22:3395-3398.
122. Mueller MM, Fusenig NE: Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation 2002;70:486-497.
123. Velasco P, Lange-Asschenfeldt B: Dermatological aspects of angiogenesis. Br J Dermatol 2002;147:841-852.
124. Zenz R, Scheuch H, Martin P, Frank C, Eferl R, Kenner L, Sibilia M, Wagner EF: c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell 2003;4:879-889.
125. Panajotovic L: Classification and stages of skin melanoma. Vojnosanit Pregl 2003;60: 211-217.
126. Hunts J, Ueda M, Ozawa S, Abe O, Pastan I, Shimizu N: Hyperproduction and gene amplifications of the EGFR in squamous cell carcinomas. Jpn J Cancer Res 1985;76:633-666.
127. Rho O, Beltran LM, Giménez-Conti IB, Di-Giovanni J: Altered expression of the epidermal growth factor receptor and transforming growth factor-alpha during multistage skin carcinogenesis in SENCAR mice. Mol Carcinog 1994;11:19-28.
128. Liu B, Zhang H, Li S, Chen W, Li R: The expression of c-erbB-1 and c-erbB-2 oncogenes in basal cell carcinoma and squamous cell carcinoma of skin. Chin Med Sci J 1996; 11:106-109.
129. Casanova ML, Larcher F, Casanova B, Murillas R, Fernandez-Acenero MJ, Villanueva C, Martinez-Palacio J, Ullrich A, Conti CJ, Jorcano JL: A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res 2002;62:3402-3407.
130. Kiguchi K, Beltran L, Rupp T, DiGiovanni J: Altered expression of epidermal growth factor receptor ligands in tumor promoter-treated mouse epidermis and in primary mouse skin tumors induced by an initiation-promotion protocol. Mol Carcinog 1998;22:73-83.
131. Sibilia M, Fleischmann A, Behrens A, Stingl L, Carroll J, Watt FM, Schlessinger J, Wagner EF: The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell 2000;102:211-220.
132. Segrelles C, Ruiz S, Perez P, Murga C, Santos M, Budunova IV, Martinez J, Larcher F, Slaga TJ, Gutkind JS, Jorcano JL, Paramio JM: Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene 2002;21:53-64.
133. Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, Cotsonis G, Cerimele F, Govindarajan B, Macaron N, Arbiser JL: Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res 2002;8:3728-3733.
134. Budiyanto A, Bito T, Kunisada M, Ashida M, Ichihashi M, Ueda M: Inhibition of the epidermal growth factor receptor suppress telomerase activity in HHSC-1 human cutaneous squamous cell carcinoma cells. J Invest Dermatol 2003;121:1088-1094.
135. Wan YS, Wang ZQ, Shao Y, Voorhees JJ, Fisher GJ: Ultraviolet irradiation activates PI3-kinase/AKT survival pathway via EGF receptors in human skin in vivo. Int J Oncol 2001;18:461-466.
136. Woodworth CD, Gaiotti D, Michael E, Hansen L, Nees M: Targeted disruption of the epidermal growth factor receptor inhibits development of papillomas and carcinomas from human papillomavirus-immortalized keratinocytes. Cancer Res 2002;60:4397-4402.
137. Shimizu T, Izumi H, Oga A, Furumoto H, Murakami T, Ofuji R, Muto M, Sasaki K: Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin. Dermatology 2001;202:203-206.
138. Fujii K, Furukawa F, Matsuyoshi N: Ligand activation of overexpressed epidermal growth factor receptor results in colony dissociation and disturbed E-cadherin function in HSC-1 human cutaneous squamous carcinoma cells. Exp Cell Res 1996;223:50-62.
139. Kiguchi K, Bol D, Carbajal S, Beltran L, Moats S, Chan K, Jorcano J, DiGiovanni J: Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development. Oncogene 2000;19:4243-4254.
140. Mimeault M, Pommery N, Hénichart JP: New advances on prostate carcinogenesis and therapies. Involvement of EGF-EGFR transduction system. Growth Factors 2003;21:1-14.
141. Arbeit JM, Olson DC, Hanahan D: Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice. Oncogene 1996;13:1847-1857.
142. Wilker E, Bol D, Kiguchi K, Rupp T, Beltran L, DiGiovanni J: Enhancement of susceptibility to diverse skin tumor promoters by activation of the insulin-like growth factor-1 receptor in the epidermis of transgenic mice. Mol Carcinog 1999;25:122-131.
143. Jee SH, Chiu HC, Tsai TF, Tsai WL, Liao YH, Chu CY, Kuo ML: The phosphatidyl inositol 3-kinase/Akt signal pathway is involved in interleukin-6-mediated Mcl-1 upregulation and anti-apoptosis activity in basal cell carcinoma cells. J Invest Dermatol 2002;119:1121-1127.
144. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H: Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002;21:7001-7010.
145. Agarwala SS: Intermediate- and high-risk melanoma. Curr Treat Options Oncol 2002;3: 205-217.
146. Kunz M, Hartmann A: Angiogenesis-antiangiogenesis. Significance for tumor growth and metastasis (in German). Hautarzt 2002; 53:373-384.
147. Kendall CA, Morton CA: Photodynamic therapy for the treatment of skin disease. Technol Cancer Res Treat 2003;2:283-288.
148. Mitchell MS: Combinations of anticancer drugs and immunotherapy. Cancer Immunol Immunother 2003;52:686-692.
149. Engleman EG: Dendritic cell-based cancer immunotherapy. Semin Oncol 2003;30:23-29.
150. Wheatley K, Ives N, Hancock B, Gore M: Interferon as adjuvant treatment for melanoma. Lancet 2002;360:878.
151. Hersey P: Adjuvant therapy for high-risk primary and resected metastatic melanoma. Intern Med J 2003;33:33-43.
152. Ahmad N, Gali H, Javed S, Agarwal R: Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression. Biochem Biophys Res Commun 1998;247: 294-301.
153. Ahmad N, Kalka K, Mukhtar H: In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy. Oncogene 2001;20:2314-2317.
154. Christensen JG, Schreck RE, Chan E, Wang X, Yang C, Liu L, Cui L, Wei J, Cherrington JM, Mendel DB: High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibits EGFR phosphorylation in vivo. Clin Cancer Res 2001;7:4230-4238.
155. Di Nardo A, Benassi L, Magnoni C, Cossarizza A, Seidenari S, Giannetti A: Ceramide 2 (N-acetyl sphingosine) is associated with reduction in Bcl-2 protein levels by Western blotting and with apoptosis in cultured human keratinocytes. Br J Dermatol 2000;143: 491-497.
156. Rylova SN, Amalfitano A, Persaud-Sawin DA, Guo WX, Chang J, Jansen PJ, Proia AD, Boustany RM: The CLN3 gene is a novel molecular target for cancer drug discovery. Cancer Res 2002;62:801-808.
157. Bektas M, Orfanos CE, Geilen CC: Different vitamin D analogues induce sphingomyelin hydrolysis and apoptosis in the human keratinocyte cell line HaCaT. Cell Mol Biol 2000; 46:111-119.
158. Casanova ML, Blázquez C, Martínez-Palacio J, Villanueva C, Fernández-Aceñero MJ, Huffman JW, Jorcano JL, Guzmán M: Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003;111:43-50.
159. Katiyar SK: Treatment of silymarin, a plant flavonoid, prevents ultraviolet light-induced immune suppression and oxidative stress in mouse skin. Int J Oncol 2002;21:1213-1222.
160. Singh RP, Agarwal R: Flavonoid antioxidant silymarin and skin cancer. Antioxid Redox Signal 2002;4:655-663.
161. Wei H, Zhang X, Wang Y, Lebwohl M: Inhibition of ultraviolet light-induced oxidative events in the skin and internal organs of hairless mice by isoflavone genistein. Cancer Lett 2002;185:21-29.
162. Bhatia N, Agarwal C, Agarwal R: Differential responses of skin cancer-chemopreventive agents silibinin, quercetin, and epigallocatechin 3-gallate on mitogenic signaling and cell cycle regulators in human epidermoid carcinoma A431 cells. Nutr Cancer 2001;39:292-299.
163. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, Lorusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110-124.
164. Han WS, Yoo JY, Youn SW, Kim DS, Park KC, Kim SY, Kim KH: Effects of C2-ceramide on the Malme-3M melanoma cell line. J Dermatol Sci 2002;30:10-19.
165. Veldman RJ, Mita A, Cuvillier O, Garcia V, Klappe K, Medin JA, Campbell JD, Carpentier S, Kok JW, Levade T: The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs. FASEB J 2003;17:1144-1146.
166. Raisova M, Goltz G, Bektas M, Bielawska A, Riebeling C, Hossini AM, Eberle J, Hannun YA, Orfanos CE, Geilen CC: Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes. FEBS Lett 2002; 516:47-52.
167. Weiss M, Hettmer S, Smith P, Ladisch S: Inhibition of melanoma tumor growth by a novel inhibitor of glucosylceramide synthase. Cancer Res 2003;63:3654-3658.
168. Deng W, Li R, Guerrera M, Liu Y, Ladisch S: Transfection of glucosylceramide synthase antisense inhibits mouse melanoma formation. Glycobiology 2002;12:145-152.
169. Leber K, Perron VD, Sinni-McKeehen B: Common skin cancers in the United States: A practical guide for diagnosis and treatment. Nurse Pract Forum. 1999;10:106-112.
170. De Rosa FS, Bentley MV: Photodynamic therapy of skin cancers: Sensitizers, clinical studies and future directives. Pharm Res 2000;17:1447-1455.
171. Agarwala SS, Kirkwood JM: Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: A phase I dose-escalation study. Cancer 2003;97:121-127.
172. Dreno B, Wallon-Dumont G: Treatment of melanoma. Presse Med 2003;32:39-43.
173. Sauter ER, Takemoto R, Litwin S, Herlyn M: p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma. Cancer Gene Ther 2002;9:807-812.
174. Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E: Synergy between tumor immunotherapy and anti-angiogenic therapy. Blood 2003;102:964-971.
175. Khayat D, Bernard-Marty C, Meric JB, Rixe O: Biochemotherapy for advanced melanoma: Maybe it is real. J Clin Oncol 2002;20: 2411-2314.
176. Agarwala S: Improving survival in patients with high-risk and metastatic melanoma: Immunotherapy leads the way. Am J Clin Dermatol 2003;4:333-346.
177. Schmittel A, Proebstle T, Engenhart-Cabillic R, Scheibenbogen C, Geueke AM, Thiel E, Keilholz U: Brain metastases following interleukin-2 plus interferon-alpha-2a therapy: A follow-up study in 94 stage IV melanoma patients. Eur J Cancer 2003;39:476-480.
178. Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, Lomax L, Ashcroft L, Thatcher N, Middleton MR: Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 2003;21:2551-2557.
179. de Gast GC, Batchelor D, Kersten MJ, Vyth-Dreese FA, Sein J, van de Kasteele WF, Nooijen WJ, Nieweg OE, de Waal MA, Boogerd W: Temozolomide followed by combined immunotherapy with GM-CSF, lowdose IL2 and IFN alpha in patients with metastatic melanoma. Br J Cancer 2003;88:175-180.
180. Fischer B, Knop J, Enk AH: Experiences with therapy of stage IV metastatic malignant melanoma with 'Legha Protocol' polychemoimmunotherapy (in German). Hautarzt 2002; 53:393-399.
181. Tuettenberg A, Jonuleit H, Tuting T, Bruck J, Knop J, Enk AH: Priming of T cells with Adtransduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor- specific CD8+ T cells: Implications for an efficient vaccination strategy. Gene Ther 2003;10:243-250.
182. Masci P, Borden EC: Malignant melanoma: Treatments emerging, but early detection is still key. Cleve Clin J Med 2002;69:529, 533-534, 536-538.
183. Joseph B, Marchetti P, Lefebvre O, Schraen-Maschke S, Mereau-Richard C, Formstecher P: The novel retinoid AHPN/CD437 induces a rapid but incomplete apoptotic response in human myeloma cells. Biochim Biophys Acta 2003;1593:277-282.